Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 45 and 85 years old
- People who have never had a prostate biopsy before
- People who have a single suspicious area in the prostate, with complete MRI scan data of acceptable quality, and a prostate imaging score (PI-RADS V2.1) greater than 3, meaning the suspicious area has been rated as moderately to highly concerning on MRI
- People whose situation meets the standard reasons for recommending a prostate biopsy — this includes having a suspicious finding on a physical rectal examination, an abnormal result on an ultrasound or MRI, a total PSA level above 10 ng/mL, or a PSA level between 4 and 10 ng/mL combined with certain other PSA ratio or density measurements (confirm with trial site)
- People whose prostate biopsy results are fully available, and where no more than one month passed between the MRI scan and the biopsy
- People who have complete medical and clinical records available
Who may not be able to join:
- People whose MRI scan data is incomplete or of insufficient quality
- People who received radiotherapy, chemotherapy, hormone therapy to reduce androgens, or any surgical treatment before their MRI scan or prostate biopsy
- People who have had a prostate biopsy in the past
- People whose prostate imaging score (PI-RADS V2.1) is below 4
- People whose situation does not meet the standard medical reasons for recommending a prostate biopsy
- People who are unable to cooperate with completing the prostate biopsy procedure
- People, or their family members, who have declined to take part in the study
- People whose clinical and medical records are incomplete
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yi LIU, Peking University First Hospital
Phone: +86 13611035261
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The clinically significant prostate cancer (csPCa) detection rate for TB+PB and TB+SB
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.